# Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT00080340** · PHASE3 · COMPLETED · sponsor: **Telik** · enrollment: 520 (—)

## Conditions studied

- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** TLK286 (Telcyta) HCl for Injection
- **DRUG:** gefitinib (Iressa)

## Key facts

- **NCT ID:** NCT00080340
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 520 (—)
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080340, "Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00080340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*